Targeted Delivery of Butyrate Improves Glucose Homeostasis, Reduces Hepatic Lipid Accumulation and Inflammation in db/db Mice
International Journal of Molecular Sciences · 25.02.2023 · 24 (5) · 4533
DOI: 10.3390/ijms24054533 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.02.2023. Verfasst von Signe Schultz Pedersen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 København, Denmark. Hauptthemen laut MEDLINE: Butyrates, Starch. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation.
Abstract (Originalsprache)
Butyrate produced by the gut microbiota has beneficial effects on metabolism and inflammation. Butyrate-producing bacteria are supported by diets with a high fiber content, such as high-amylose maize starch (HAMS). We investigated the effects of HAMS- and butyrylated HAMS (HAMSB)-supplemented diets on glucose metabolism and inflammation in diabetic db/db mice. Mice fed HAMSB had 8-fold higher fecal butyrate concentration compared to control diet-fed mice. Weekly analysis of fasting blood glucose showed a significant reduction in HAMSB-fed mice when the area under the curve for all five weeks was analyzed. Following treatment, fasting glucose and insulin analysis showed increased homeostatic model assessment (HOMA) insulin sensitivity in the HAMSB-fed mice. Glucose-stimulated insulin release from isolated islets did not differ between the groups, while insulin content was increased by 36% in islets of the HAMSB-fed mice. Expression of insulin 2 was also significantly increased in islets of the HAMSB-fed mice, while no difference in expression of insulin 1, pancreatic and duodenal homeobox 1, MAF bZIP transcription factor A and urocortin 3 between the groups was observed. Hepatic triglycerides in the livers of the HAMSB-fed mice were significantly reduced. Finally, mRNA markers of inflammation in liver and adipose tissue were reduced in mice fed HAMSB. These findings suggest that HAMSB-supplemented diet improves glucose metabolism in the db/db mice, and reduces inflammation in insulin-sensitive tissues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 København, Denmark.
- Steno Diabetes Center Copenhagen, 2730 Herlev, Denmark.
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 København, Denmark.
- Infection and Immunity Program, Biomedicine Discovery Institute, Department of Biochemistry, Monash University, Melbourne, VIC 3800, Australia.
ORCID-Profile: Thomas Moritz, Eliana Mariño
Förderung
- Novo Nordisk Foundation
Zitieren
APA
Pedersen, S. S., Prause, M., Sørensen, C., Størling, J., Moritz, T., Mariño, E., & Billestrup, N. (2023). Targeted Delivery of Butyrate Improves Glucose Homeostasis, Reduces Hepatic Lipid Accumulation and Inflammation in db/db Mice. International Journal of Molecular Sciences, 24(5), 4533. https://doi.org/10.3390/ijms24054533
Vancouver
Pedersen SS, Prause M, Sørensen C, Størling J, Moritz T, Mariño E, et al. Targeted Delivery of Butyrate Improves Glucose Homeostasis, Reduces Hepatic Lipid Accumulation and Inflammation in db/db Mice. International Journal of Molecular Sciences. 2023;24(5):4533. doi:10.3390/ijms24054533
BibTeX
@article{Pedersen2023,
author = {Pedersen, Signe Schultz and Prause, Michala and Sørensen, Christina and Størling, Joachim and Moritz, Thomas and Mariño, Eliana and Billestrup, Nils},
title = {Targeted Delivery of Butyrate Improves Glucose Homeostasis, Reduces Hepatic Lipid Accumulation and Inflammation in db/db Mice},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {5},
pages = {4533},
doi = {10.3390/ijms24054533}
}
EUVIMED